This meeting is on from today the 16th to the 18th. So Kilian is...

This meeting is on from today the 16th to the 18th.

So Kilian is telling shareholders data we aren't able to see in the announcement (and I would love to see as its likely to be extremely relevant to my investment and because I have extreme reservations about management doing much of anything value adding and so would like to see something substantive and scientific) is going to be shared with a bunch of academics and associated hang a rounders at a meeting.

If I post the language I want to use to express what I think is entirely legitimate frustration my post with be censored for obscenity.

KILIAN AS A SHAREHOLDER I AM SICK OF READING TALK DOWN, DUMBED DOWN, SPIN ABOUT DATA BEING PRESENTED TO OTHER PEOPLE (giving them an advantage in the market over me as its data I can't see) - I WANT TO SEE THE ACTUAL DATA. !!!!!!



Kilian I don't want you summarising the key findings for me - I don't trust you any longer frankly to know what the key findings are or to represent them objectively and impartially without spinning them.

You write in bold

"The overall conclusion of the study is that Cymerus MSCs are highly consistent and that the Cymerus manufacturing process successfully bypasses much of the inherent variability that affects tissue-derived MSCs. "

Much? So what doesn't it bypass?

"Product consistency is a mandatory requirement of healthcare regulatory agencies such as the FDA and so the conclusions from this study further support the utility of the Cymerus platform"

.....Yes it is.

.... I do not accept or believe that that logically follows. Absolutely nothing in the information announced today amounts to further support as everything in the little you are telling us the company had already given us every reason to believe was the case already. All that appears to be happening is that a bit of back filling research is being down that partly bears out what the company has been suggesting to be true for a very long time. I say partly because you said much.

"The study validates the potential of Cymerus MSCs as an off-the-shelf cell therapy and provides a better understanding of the sources of MSC variability, with a view to making clinical outcomes more predictable"

--------------------- (re the underlined bit) I don't believe the study does validate the potential of Cymerus MSCs as an off-the-shelf cell therapy product - unless you make the word potential do a heck of a lot of work in watering down the implications of the rest of that sentence. Until CYP can show commerical scale (not clincial trial scale) manufacturing it is begging the question and presuming the answer to assume that CYmerus MSCs (without other tech in support) will be sufficient for off-the-shelf cell therapies. If we are making cells in 2D manufacturing paradigms using 10 litres of media at critical steps we aren't at off-the-shelf scales yet - that case isn't made. I'll say in my opinion. But I think its more than just that. I believe its fanciful to pretend to have off-the-shelf cell therapy unless you can put a cost of manufacture on that 'potential' therapy. And you can't credibly do that until you can rule in or out 3D manufacturing as an alternative. Your notion of "off-the-shelf" even potentially is premature Kilian. In my opinion.

.... If you can't offer better than "with a view to making clinical outcomes more predictable" then its little surprise we have no commercial partners to speak of. The end value that needs to be born in mind is that if medicines can't be made that can be sold that will at a minimum recoup their costs of manufacturing then all the clinical trial stuff is just necessary but not sufficient.